Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells
- 1 April 2015
- journal article
- research article
- Published by Elsevier in Clinical Biochemistry
- Vol. 48 (6) , 406-411
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Expression of Calcineurin Activity after Lung Transplantation: A 2-Year Follow-UpPLOS ONE, 2013
- Neutrophils in the pathogenesis and manifestations of SLENature Reviews Rheumatology, 2011
- Reduced-Dose Tacrolimus with Mycophenolate Mofetil vs. Standard-Dose Tacrolimus in Liver Transplantation: A Randomized StudyAmerican Journal of Transplantation, 2011
- Refining the white blood cell differential: The first flow cytometry routine applicationCytometry Part A, 2010
- Deficiency in calcineurin activity in liver transplantation candidates with alcoholic cirrhosis or hepatocellular carcinomaLiver International, 2009
- Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Peripheral Blood Mononuclear CellsTherapeutic Drug Monitoring, 2009
- Pharmacokinetic-Pharmacodynamic Assessment of Tacrolimus in Liver-Transplant Recipients during the Early Post-Transplantation PeriodTherapeutic Drug Monitoring, 2008
- Variation in Leukocyte Subset Concentrations Affects Calcineurin Activity Measurement: Implications for Pharmacodynamic Monitoring StrategiesClinical Chemistry, 2008
- Distribution of calcineurin activity in blood cell fractions and impact of tacrolimus inhibitionFundamental & Clinical Pharmacology, 2006
- DEFECTIVE INHIBITION OF PERIPHERAL CD8+ T CELL IL-2 PRODUCTION BY ANTI-CALCINEURIN DRUGS DURING ACUTE LIVER ALLOGRAFT REJECTIONTransplantation, 2004